




## Supplementary Figures & Legends

**Figure S1. Mesenchymal phenotype is induced in HUVECs through contact with tumor cells**



- A) Flow cytometry overlays demonstrating stable expression of endothelial markers CD31 and VE-Cadherin in HUVECs after having contact with MDA-231 tumor cells. HUVECs were co-cultivated with MDA-231 breast cancer cells under starvation for 3-5 days, stained with endothelial markers (CD31 and VE-Cadherin) and analyzed by flow cytometry.
- B) Flow cytometry overlays displaying the up-regulation of mesenchymal phenotypes in HUVECs after contact with MDA-231 BCCs. Our results confirmed the acquisition of mesenchymal phenotype by HUVECs by showing the up-regulation of  $\alpha$ -SMA (about 70%) and FSP-1 (about 20%) of of HUVECs.


**Figure S2. Mesenchymal phenotype is initiated in ECs through contact with MCF-7**



## Figure S2. Mesenchymal phenotype is initiated in ECs through contact with MCF-7 breast cancer cells

- A) Confocal images and flow cytometry overlays show that endothelial phenotype in ECs<sup>Mes</sup> is maintained after contact with MCF-7 BCCs as shown by CD31 and VE-Cadherin staining. However, our results confirmed that MCF-7 cells were capable of inducing mesenchymal phenotype in ECs<sup>Mes</sup> as demonstrated by up-regulation of FN1, vimentin (left panels)  $\alpha$ -SMA and F-actin stress fibers (right panels). White arrows in some images show the MCF-7 cells in co-culture with GFP<sup>+</sup>ECs. Scale bars represent 20  $\mu$ m.
- B) Semi-quantitative qPCR further validated our results by showing that ECs<sup>Mes</sup> sorted from MCF-7 BCCs also maintained their endothelial phenotypes while over-expressed mesenchymal markers. (\*\* $p < 0.01$ , mean  $\pm$  SEM, n=3)

Figure S3. MDA-231 conditioned media (CM) does not induce a mesenchymal phenotype in ECs.




**Figure S3. MDA-231 conditioned media (CM) does not induce a mesenchymal phenotype in ECs.**

- A) Flow cytometry overlays demonstrating stable expression of endothelial markers CD31 and VE-Cadherin in ECs grown in MDA-231 starvation CM for 3-5 days.
- B) Flow cytometry overlays displaying stable mesenchymal phenotypes in ECs grown in MDA-231 starvation CM. Our results confirmed the importance of direct cell-to-cell contact between BCCs and ECs in triggering the transition to a mesenchymal phenotype in ECs.

**S4. An Excel sheet containing full gene list of the IPA functional gene clustering has been uploaded for creation of a hyperlink.**


**Figure S5. Flow cytometry scatter plots illustrate gating for PE+MDA-231 and GFP+ECs for sorting**



BCCs were stained with a PE-conjugated PKH26 dye (Sigma) before a co-culture was set up with GFP +ECs. After 3-5 days of co-cultivation, BCCs and ECs were gated using their PE and GFP fluorescent, respectively. GFP fluorescence was acquired using 488 nm blue laser and 510/50 nm emission. PE fluorescent was acquired using 496/566 nm blue laser and 576 nm emission to separate BCCs from GFP +ECs and sorting was done using purity masks.




**Figure S6. Mesenchymal phenotype is reversed once EC contact with cancer cells is disrupted**



**Figure S6. The EC mesenchymal property is reversed once their contact with cancer cells is disrupted**


- A) Schematic representation of the experimental procedure performed for obtaining EC<sup>Reversed</sup>. ECs<sup>Mes</sup> were sorted from BCCs and continued to grow and passage without any contact with BCCs under normal condition for 10-15 days to obtain EC<sup>Reversed</sup>. These cells were then examined for the maintenance of mesenchymal phenotype in comparison to ECs<sup>Norm</sup> and ECs<sup>Mes</sup>.
- B) Confocal microscopy images display the endothelial and mesenchymal properties of EC<sup>Reversed</sup> compared to ECs<sup>Norm</sup> and ECs<sup>Mes</sup>. As expected, endothelial properties were stable in all three conditions; however, the mesenchymal phenotype was reversed in ECs<sup>Reversed</sup> 10-15 days after sorting from BCCs as indicated by down-regulation of mesenchymal marker FN1 and F-actin. Scale bars are representative of 20  $\mu$ m.
- C) Semi-quantitative qPCR analysis of endothelial and mesenchymal phenotypes in EC<sup>Reversed</sup> compared to ECs<sup>Norm</sup> and ECs<sup>Mes</sup>. In line with our confocal results, qPCR showed stable expression of CD31 and VE-Cad endothelial markers, while there was a reversion of mesenchymal phenotype in EC<sup>Reversed</sup> compared to ECs<sup>Mes</sup>.
- D) A wound healing assay performed to show and quantify the migratory capability of EC<sup>Reversed</sup> several passages post-sorting from MDA-231 tumor cells as compared with EC<sup>Mes</sup>.
- E) A tube formation assay evaluates and measures the angiogenic property of EC<sup>Reversed</sup> on matrigel. (\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$ , mean  $\pm$  SEM, n=3 )

Figure S7. Proliferation of MCF-7 in co-culture with ECs<sup>Norm</sup> or ECs<sup>Mes</sup>.



Cell proliferation assay showing proliferation of MCF-7 cancer cells when co-cultured with ECs<sup>Mes</sup> or ECs<sup>Norm</sup>. Once MCF-7 cells were grown with ECs<sup>Mes</sup>, they showed around 1.6-fold higher proliferation rate than when grown with ECs<sup>Norm</sup>.

**Figure S8**



## Figure S8.

- A) Western blot band densitometry showing the up-regulation of p-Smad5 in response to treating ECs<sup>Norm</sup> with Jag1 or TGF $\beta$  or both ligands compared to total Smad5 protein (left bar graph). To show a synergy between Jag1 and TGF $\beta$  in activation of Smad5, we showed up-regulation of notch downstream effector Hes-1 once ECs<sup>Norm</sup> were supplemented with the ligands (right bar graph). The highest level of Hes-1 activation is observed once ECs<sup>Norm</sup> were treated with both ligands.
- B) Western blot band densitometry demonstrating that inhibition of notch and/or TGF $\beta$  pathways by GSI and SB, respectively significantly down-regulated phosphorylation of Smad5 in ECs<sup>Mes</sup> once ECs<sup>Mes</sup> were treated with both inhibitors (left bar graph). This finding confirms the involvement of both pathways in Smad5 activation. Also, the lowest level of Hes-1 expression was found in ECs<sup>Mes</sup> treated with both inhibitors (right bar graph) showing a synergy between the two pathways.
- C) Flow cytometry overlays further confirming a role for TGF $\beta$  and notch pathways in regulation of tumor-induced mesenchymal transformation of ECs<sup>Mes</sup>. Treating ECs<sup>Mes</sup> with TGF $\beta$  and notch inhibitors resulted in down-regulation of mesenchymal markers such as  $\alpha$ -SMA and vimentin in ECs<sup>Mes</sup> as compared to ECs<sup>Norm</sup> and ECs<sup>Mes</sup> without inhibitors.
- D) qPCR analysis of Jagged1 down-regulation in MDA-231 cells transfected with shRNA against Jag1.
- E) qPCR analysis showing lack of activation of notch downstream effector molecules in ECs once they were exposed to MDA-231<sup>Jag1-KD</sup> cells further confirming Jag1 silencing on MDA-231 cells.

**Supplementary Table S1. List of Primers**

<b>Primer Name</b>	<b>Forward</b>	<b>Reverse</b>
<b>FN1</b>	CAGTGGGAGACCTCGAGAAG	TCCCTCGGAACATCAGAAAC
<b>Snail</b>	CCTCCCTGTCAGATGAGGAC	CCAGGCTGAGGTATTCCTTG
<b>CD31</b>	AAGTGGAGTCCAGCCGCATATC	ATGGAGCAGGACAGGTTTCAGTC
<b>VE-Cad</b>	GAAGCCTCTGATTGGCACAGTG	TTTTGTGACTCGGAAGAACTGGC
<b>Slug</b>	GGGGAGAAGCCTTTTTCTTG	TCCTCATGTTTGTGCAGGAG
<b>FSP1</b>	GAGGCTTTACTCGCACTTCG	ACCCTACGCAGACTCCCAG
<b><math>\alpha</math>-SMA</b>	CTGACAGAGGCACCACTGAA	CATCTCCAGAGTCCAGCACA
<b>Jag1</b>	TCGCTGTATCTGTCCACCTG	AGTCACTGGCACGGTTGTA
<b>Hey1</b>	TGTCTGAGCTGAGAAGGCTGG	TTCAGGTGATCCACGGTCATC
<b>Hes1</b>	ATGGAGAAAAATTCCTCGTCC	TTCAGAGCATCCAAAATCAGT
<b>GAPDH</b>	AGCCACATCGCTCAGACAC	GCCCAATACGACCAAATCC